Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue , 2014, Pages 349-356

  Levy, Florence ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

ADHD; Alpha 2 agonists; COMT; Dopamine receptors; Dopamine transporter; Stimulant side effects

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CENTRAL STIMULANT AGENT; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; METHYLPHENIDATE; NICOTINE;

ADVERSE DRUG REACTION; ADVERSE OUTCOME; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; DIAGNOSTIC TEST; DISEASE COURSE; DOPAMINERGIC SYSTEM; HUMAN; NAUSEA; NEUROPHYSIOLOGY; NONHUMAN; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; PHARMACOGENETICS; PREFRONTAL CORTEX; REVIEW; SUBCORTEX; TREATMENT RESPONSE; ZOMBIE LIKE SYMPTOM;

EID: 84924916231     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S52844     Document Type: Review

References (37)

1. Faraone SV, Sergeant J, Gillberg C, Biederman J. The world wide prevalence of ADHD: is it an American condition? World Psychiatry. 2(2):104-113.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association; 2013.
3. Arnsten AF. Catecholamine and second messenger influences on pre­frontal cortical networks of “representational knowledge”: a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex. 2007;17 Suppl 1:i6-i15.
4. Park L, Nigg JT, Waldman ID, et al. Association and linkage of α-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol Psychiatry. 2005;10(6):572-580.
5. Levy F. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. Aust N Z J Psychiatry. 2009;43(2):101-108.
6. Levy F. Stimulant side effects and inverted-U: implications for ADHD guidelines. Aust N Z J Psychiatry. 2013a;47(3):217-221.
7. Arnsten AFT, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behav Brain Funct. 2005;1(1):2.
8. Gamo NJ, Wang M, Arnsten AFT. Methylphenidate and atomoxetine enhance prefrontal function through α2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry. 2010;49(10):1011-1023.
9. Carboni E, Cadeddu R, Carta AR. Role of prefrontal cortex dopamine and noradrenaline circuitry in addiction. In: Belin D, editors. Addictions: From Pathophysiology to Treatment. Rijeka, Croatia: InTech; 2012:129-168.
10. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci. 2007;10(3):376-384.
11. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29(11):1943-1961.
12. Keeler JF, Pretsell DO, Robbins TW. Functional implications of dop­amine D1 vs D2 receptors: A ‘prepare and select’ model of the striatal direct vs indirect pathways. Neuroscience. 2014;282C:156-175.
13. Surmeier DJ, Ding J, Day M, Wang Z, Shen W. D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci. 2007;30(5):228-235.
14. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 1989;12(10):366-375.
15. Trantham-Davidson H, Neely LC, Lavin A, Seamans JK. Mechanisms underlying differential D1 versus D2 dopamine receptor regula­tion of inhibition in prefrontal cortex. J Neurosci. 2004;24(47): 10652-10659.
16. Hill M, Anney RJ, Gill M, Hawi Z. Functional analysis of intron 8 and 3′ UTR variable number of tandem repeats of SLC6A3: differ­ential activity of intron 8 variants. Pharmacogenomics J. 2010;10(5):442-447.
17. Cook EH Jr, Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet. 1995;56(4):993-998.
18. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M. Confirmation of asso­ciation between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry. 1997;2(4):311-313.
19. Waldman ID, Rowe DC, Abramowitz A, et al. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet. 1998;63(6):1767-1776.
20. Bellgrove MA, Hawi Z, Kirley A, Gill M, Robertson IH. Dissecting the attention deficit hyperactivity disorder (ADHD) phenotype: sustained attention, response variability and spatial attentional asymmetries in relation to dopamine transporter (DAT1) genotype. Neuropsychologia. 2005a;43(13):1847-1857.
21. Manly T, Owen AM, McAvinue L, et al. Enhancing the sensitivity of a sustained attention task to frontal damage: convergent clinical and functional imaging evidence. Neurocase. 2003;9(4):340-349.
22. Bellgrove MA, Hawi Z, Kirley A, Fitzgerald M, Gill M, Robertson IH. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder. Neuropsychopharmacology. 2005;30(12):2290-2297.
23. Tomasi D, Volkow ND, Wang R, et al. Dopamine transporters in stria­tum correlate with deactivation in the default mode network during visuospatial attention. PLoS ONE. 2009;4(6):e6102.
24. Kambeitz J, Romanos M, Ettinger U. Meta-analysis of the association between dopamine transporter genotype and response to methylpheni­date treatment in ADHD. Pharmacogenomics J. 2014;14(1):77-84.
25. Braet W, Johnson KA, Tobin CT, et al. fMRI activation during response inhibition and error processing: the role of the DAT1 gene in typically developing adolescents and those diagnosed with ADHD. Neuropsychologia. 2011;49(7):1641-1650.
26. Cummins TD, Hawi Z, Hocking J, et al. Dopamine transporter geno­type predicts behavioural and neural measures of response inhibition. Mol Psychiatry. 2012;17(11):1086-1092.
27. Kim BN, Kim JW, Cummins TDR, et al. Norepinephrine genes predict response time variability and methylphenidate-induced changes in neuropsychological function in attention deficit hyperactivity disorder. J Clin Psychopharmacol. 2013;33(3):356-362.
28. Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol. 2006;6(1):6.
29. Levy F, Wimalaweera S, Moul C, Brennan J, Dadds MR. Dopamine receptors and the pharmacogenetics of side-effects of stimulant treat­ment for attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2013;23(6):423-425.
30. Stein MA, Waldman I, Newcorn J, Bishop J, Kittles R, Cook EH Jr. Dopamine transporter genotype and stimulant dose-response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2014;24(5):238-244.
31. Spencer TJ, Biederman J, Faraone SV, et al. Functional genomics of attention-deficit/hyperactivity disorder (ADHD) risk alleles on dop­amine transporter binding in ADHD and healthy control subjects. Biol Psychiatry. 2013;74(2):84-89.
32. Markowitz JS, Zhu H-J, Patrick KS. Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopamin­ergic activity and reduced drug interaction liability. J Child Adolesc Psychopharmacol. 2013;23(10):648-654.
33. Potter AS, Newhouse PA. Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2004;176(2):182-194.
34. Levin ED, McClernon FJ, Rezvani AH. Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology (Berl). 2006;184(3-4): 523-539.
35. Levin ED, Christopher NC. Persistence of nicotinic agonist RJR 2403 induced working memory improvement in rats. Drug Dev Res. 2002;55(2):97-103.
36. Levin ED, Bettegowda C, Blosser J, Gordon J. AR-R17779, and alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol. 1999;10(6-7):675-680.
37. Wilens TE, Biederman J, Spencer TJ, et al. A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1999;156(12): 1931-1937.